1. The Transparency Directive — Is it Working?

   • M. L. Burstall

   The Transparency Directive 15 November 2012 Pages: 1 - 8

2. Price Regulation, Industry Structure and Innovation

   • Lacy Glenn Thomas III

   Comparison of Pharmaceutical Industries 15 November 2012 Pages: 9 - 12

3. Rising Research and Development Costs for New Drugs in a Cost Containment Environment

   • Joseph A. Di Masi

   Research and Development Costs in Cost Containment 15 November 2012 Pages: 13 - 20

4. The Reimbursement Factor in Pharmaceutical Regulation

   • Sheila R. Shulman

   Reimbursement in Pharmaceutical Regulation 15 November 2012 Pages: 21 - 27

5. US Medicaid Drug Formularies

   • William J. Moore
   • Robert J. Newman

   Medicaid Drug Formularies 15 November 2012 Pages: 28 - 31

6. The Effect of Medicaid Formularies on the Availability of New Drugs

   • Henry G. Grabowski
   • Stuart O. Schweitzer
   • S. Renee Shiota

   Medicaid Formularies and New Drug Availability 15 November 2012 Pages: 32 - 40

7. Clinical Aspects of Therapeutic Substitution

   • Richard A. Levy

   Clinical Aspects of Therapeutic Substitution 15 November 2012 Pages: 41 - 44

8. Improving the Quality and Cost—Effectiveness of Prescribing

   • Jerry Avorn

   Improving Prescribing Practices 15 November 2012 Pages: 45 - 48

9. Comparative Potency and Dissolution Performance of Internationally Available Piroxicam Products

   • Joseph A. Barone

   Potency and Dissolution of Piroxicam Products 15 November 2012 Pages: 49 - 52

10. Challenging Official Health Cost Estimates

    • Aldona Robbins
    • Gary Robbins

    Challenging Health Cost Estimates 15 November 2012 Pages: 53 - 60

11. Australian Guidelines for Cost—Effectiveness Studies of Pharmaceuticals

    • Michael Drummond

    Cost—Effectiveness of Pharmaceuticals 15 November 2012 Pages: 61 - 69

12. Is Parallel Trade in Medicines Compatible with the Single European Market?

    • Ian Senior

    Parallel Trade in Medicines in Europe 15 November 2012 Pages: 70 - 76